Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480)
South Korea · Delayed Price · Currency is KRW 7,010.00
+10.00 (0.14%)
Last updated: Nov 11, 2025, 11:57 AM KST
KOSDAQ:036480 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 25,862 | 23,804 | 25,562 | 25,500 | 23,997 | 24,801 | Upgrade |
Other Revenue | - | -0 | -0 | -0 | -0 | - | Upgrade |
| 25,862 | 23,804 | 25,562 | 25,500 | 23,997 | 24,801 | Upgrade | |
Revenue Growth (YoY) | 7.03% | -6.88% | 0.24% | 6.26% | -3.24% | -1.32% | Upgrade |
Cost of Revenue | 18,568 | 19,872 | 20,857 | 20,855 | 18,404 | 16,903 | Upgrade |
Gross Profit | 7,293 | 3,932 | 4,705 | 4,645 | 5,593 | 7,898 | Upgrade |
Selling, General & Admin | 4,892 | 4,772 | 4,789 | 4,354 | 4,694 | 5,081 | Upgrade |
Amortization of Goodwill & Intangibles | 121.33 | 139.81 | 190.8 | 200.28 | 131.44 | 91.2 | Upgrade |
Other Operating Expenses | 91.88 | 88.62 | 87.27 | 82.98 | 122.37 | 114.9 | Upgrade |
Operating Expenses | 5,581 | 5,484 | 5,394 | 4,973 | 5,256 | 5,980 | Upgrade |
Operating Income | 1,713 | -1,552 | -689.01 | -327.52 | 337.11 | 1,918 | Upgrade |
Interest Expense | -618.53 | -846.16 | -892.67 | -512.58 | -277.53 | -11.19 | Upgrade |
Interest & Investment Income | 226.26 | 296.55 | 374.42 | 213.88 | 119.03 | 152.32 | Upgrade |
Earnings From Equity Investments | 0.48 | -27.7 | 36.39 | -14.6 | -4.97 | - | Upgrade |
Currency Exchange Gain (Loss) | 312.62 | 548.48 | 58.67 | 478.31 | 566.84 | -443.49 | Upgrade |
Other Non Operating Income (Expenses) | -109.61 | -6.56 | 30.83 | 205.01 | 95.4 | -97.95 | Upgrade |
EBT Excluding Unusual Items | 1,524 | -1,587 | -1,081 | 42.49 | 835.87 | 1,517 | Upgrade |
Gain (Loss) on Sale of Investments | -0.04 | -0.19 | -0.29 | -0.91 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 25.86 | 16.26 | -0.07 | 2,219 | 7 | 11.72 | Upgrade |
Pretax Income | 1,550 | -1,571 | -1,082 | 2,261 | 842.87 | 1,529 | Upgrade |
Income Tax Expense | 206.67 | 198.32 | -402.05 | 557.38 | -23.05 | 10.55 | Upgrade |
Net Income | 1,343 | -1,769 | -679.68 | 1,703 | 865.92 | 1,519 | Upgrade |
Net Income to Common | 1,343 | -1,769 | -679.68 | 1,703 | 865.92 | 1,519 | Upgrade |
Net Income Growth | - | - | - | 96.69% | -42.98% | -38.54% | Upgrade |
Shares Outstanding (Basic) | - | 4 | 4 | 4 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | - | 4 | 4 | 4 | 4 | 4 | Upgrade |
EPS (Basic) | - | -465.62 | -178.86 | 448.21 | 227.87 | 399.64 | Upgrade |
EPS (Diluted) | - | -465.62 | -178.86 | 448.21 | 227.87 | 399.64 | Upgrade |
EPS Growth | - | - | - | 96.69% | -42.98% | -38.54% | Upgrade |
Free Cash Flow | 1,241 | 1,308 | -2,490 | -1,160 | -764.71 | -10,770 | Upgrade |
Free Cash Flow Per Share | - | 344.14 | -655.25 | -305.18 | -201.24 | -2834.19 | Upgrade |
Gross Margin | 28.20% | 16.52% | 18.40% | 18.22% | 23.31% | 31.85% | Upgrade |
Operating Margin | 6.62% | -6.52% | -2.70% | -1.28% | 1.41% | 7.73% | Upgrade |
Profit Margin | 5.19% | -7.43% | -2.66% | 6.68% | 3.61% | 6.12% | Upgrade |
Free Cash Flow Margin | 4.80% | 5.49% | -9.74% | -4.55% | -3.19% | -43.43% | Upgrade |
EBITDA | 3,192 | 163.17 | 2,173 | 2,378 | 2,875 | 3,865 | Upgrade |
EBITDA Margin | 12.34% | 0.69% | 8.50% | 9.33% | 11.98% | 15.59% | Upgrade |
D&A For EBITDA | 1,479 | 1,715 | 2,862 | 2,706 | 2,538 | 1,948 | Upgrade |
EBIT | 1,713 | -1,552 | -689.01 | -327.52 | 337.11 | 1,918 | Upgrade |
EBIT Margin | 6.62% | -6.52% | -2.70% | -1.28% | 1.41% | 7.73% | Upgrade |
Effective Tax Rate | 13.34% | - | - | 24.66% | - | 0.69% | Upgrade |
Advertising Expenses | - | 149.24 | 176.8 | 51.04 | 122.44 | 93.24 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.